Clinical TrialsThe company continues to advance lead asset FB102 towards topline data in celiac disease, with almost half of the patients completing the trial without discontinuations, suggesting good tolerability.
Drug DevelopmentFB102 shows greater potency than observed with competing IL-15 mAbs like AMGN's ordesekimab (AMG-714) and NVS's CALY-002.
Financial PerformanceForte Biosciences reported Q4 operational expenses of $7M, below the estimated $9M.